PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
about
ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells.Melanoma: a prototype of cancer-testis antigen-expressing malignancies.Treatment of uveal melanoma: where are we now?DNA Methylation and Uveal Melanoma.Recent advancements in the management of retinoblastoma and uveal melanoma.Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions.
P2860
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
@ast
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
@en
type
label
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
@ast
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
@en
prefLabel
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
@ast
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
@en
P2093
P2860
P1433
P1476
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma
@en
P2093
Dirk M van der Steen
Ekaterina S Jordanova
Gregorius P M Luyten
Gülçin Gezgin
J William Harbour
Jinfeng Cao
Karoly Szuhai
Martine J Jager
Matthew G Field
Mehmet Dogrusöz
P2860
P304
P356
10.1001/JAMAOPHTHALMOL.2017.0729
P407
P577
2017-06-01T00:00:00Z